Effects of simvastatin on human T cells in vivo
2007 (English)In: Atherosclerosis, ISSN 0021-9150, Vol. 193, no 1, 186-192 p.Article in journal (Refereed) Published
Objective: The use of statins has shown several anti-inflammatory actions, including modulatory effects on T cells in vitro. Since the effects on human T cells in vivo are less clarified, our aim was to investigate the effects of simvastatin on human T cells in vivo and ex vivo. Methods and results: A randomized, double-blind, placebo-controlled study design was applied. Eighty volunteers with mild to moderate hypercholesterolemia received either simvastatin 40 mg or placebo for 6 weeks. The serum levels of C-reactive protein (CRP) were significantly reduced by simvastatin. The proportions of CD4+ and CD8+ T cell subsets expressing early (CD25) or late (HLA-DR) activation markers, as assessed by flow cytometry, were not changed by simvastatin. However, simvastatin tended to increase the density of HLA-DR and L-selectin per CD8+ T cell. The T helper(h)1/Th2 response was evaluated by stimulatory assays followed by intra-cellular staining of interferon-γ and interleukin-4. Simvastatin treatment did not affect the Th1 response but the results indicated a potential to suppress Th2. Conclusion: Simvastatin treatment resulted in a few discrete changes as regards peripheral T cells. However, the findings do not provide evidence that simvastatin-induced anti-inflammatory actions are related to any significant modulatory effects on human T cells in clinically healthy men with hypercholesterolemia. © 2006 Elsevier Ireland Ltd. All rights reserved.
Place, publisher, year, edition, pages
2007. Vol. 193, no 1, 186-192 p.
atherosclerosis; inflammation, T cell, HMG-CoA reductase inhibitor
National CategoryMedical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-37701DOI: 10.1016/j.atherosclerosis.2006.06.022Local ID: 37705OAI: oai:DiVA.org:liu-37701DiVA: diva2:258550